The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels
Matrix -carboxyglutamic acid (MGLA) protein is a vitamin K dependent peptide which contributes to the immunomodulatory activity of mesenchymal stromal cells. There is a possible association between MGLA protein and inflammatory bowel disease (IBD) which is divided into Crohn’s disease (CD) and ulce...
Gespeichert in:
| Veröffentlicht in: | The Egyptian journal of immunology 2024-10, Vol.31 (4), p.85-97 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 97 |
|---|---|
| container_issue | 4 |
| container_start_page | 85 |
| container_title | The Egyptian journal of immunology |
| container_volume | 31 |
| creator | Mohamed, Ghada |
| description | Matrix -carboxyglutamic acid (MGLA) protein is a vitamin K dependent peptide which contributes to the immunomodulatory activity of mesenchymal stromal cells. There is a possible association between MGLA protein and inflammatory bowel disease (IBD) which is divided into Crohn’s disease (CD) and ulcerative colitis (UC). However, little is known about the clinical utility of MGLA protein in IBD patients. This study aimed to assess the impact of achieving remission on the serum MGLA protein levels in IBD patients. This prospective observational study included 60 newly diagnosed IBD patients. All patients were subjected to full clinical, laboratory, radiological, and histopathological assessment of IBD at baseline and six months after initiating treatment. Serum MGLA protein level was assessed using an enzyme-linked immunosorbent assay. There were 29 (48.3%) UC cases and 31 (51.67%) CD cases. We observed a significant decrease in serum MGLA protein levels after 6 months of treatment compared to pretreatment values in UC patients (120.490 ± 26.273 vs. 26.320 ± 17.378 nmol/L, p |
| doi_str_mv | 10.55133/eji.310409 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_55133_eji_310409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_55133_eji_310409</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_55133_eji_3104093</originalsourceid><addsrcrecordid>eNqVj11qwzAQhEVpIabNUy6w78Xpyo5j_FxaeoC8i42zThSkyGjVNH7saXq8XqHqzwUKAwMzw8Cn1ELjsml0XT_w0S5rjSvsrlRRYYdl1eD6WhVaayxXHVYzNRc5IqKumnbdtoVKmwOD9SP1CcIA1B8sn-1pD5G9FbHhBPZbgyPvKYU4wTa8sYOdFSZhyIPRkXiCXEd7gc_3j7KnuA2Xae9eE-WYYYwhcT5yfGYnd-pmICc8__Nbdf_8tHl8KfsYRCIPZozWU5yMRvPDZjKb-WWr_7f-AtGRWV4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels</title><source>Alma/SFX Local Collection</source><creator>Mohamed, Ghada</creator><creatorcontrib>Mohamed, Ghada ; Department of Internal Medicine, Gastroenterology & Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt</creatorcontrib><description><![CDATA[Matrix -carboxyglutamic acid (MGLA) protein is a vitamin K dependent peptide which contributes to the immunomodulatory activity of mesenchymal stromal cells. There is a possible association between MGLA protein and inflammatory bowel disease (IBD) which is divided into Crohn’s disease (CD) and ulcerative colitis (UC). However, little is known about the clinical utility of MGLA protein in IBD patients. This study aimed to assess the impact of achieving remission on the serum MGLA protein levels in IBD patients. This prospective observational study included 60 newly diagnosed IBD patients. All patients were subjected to full clinical, laboratory, radiological, and histopathological assessment of IBD at baseline and six months after initiating treatment. Serum MGLA protein level was assessed using an enzyme-linked immunosorbent assay. There were 29 (48.3%) UC cases and 31 (51.67%) CD cases. We observed a significant decrease in serum MGLA protein levels after 6 months of treatment compared to pretreatment values in UC patients (120.490 ± 26.273 vs. 26.320 ± 17.378 nmol/L, p<0.001) and CD patients (125.576 ± 28.208 vs. 28.520 ± 18.443 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent UC patients before treatment (142.556 ± 17.096 vs. 110.560 ± 23.659 nmol/L, p<0.001) and after six months of treatment (51.222 ± 4.410 vs. 15.114 ± 3.302 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent CD patients before treatment (150.727 ± 7.198 vs. 111.743 ± 25.718 nmol/L, p<0.001) and after six months of treatment (52.182 ± 5.269 vs. 15.506 ± 4.475 nmol/L, p<0.001). This response was irrespective of the therapeutic modality. In conclusion, achievement of remission in IBD patients resulted in a significant decrease in serum MGLA protein levels.]]></description><identifier>ISSN: 1110-4902</identifier><identifier>EISSN: 2090-2506</identifier><identifier>DOI: 10.55133/eji.310409</identifier><language>eng</language><ispartof>The Egyptian journal of immunology, 2024-10, Vol.31 (4), p.85-97</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Mohamed, Ghada</creatorcontrib><creatorcontrib>Department of Internal Medicine, Gastroenterology & Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt</creatorcontrib><title>The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels</title><title>The Egyptian journal of immunology</title><description><![CDATA[Matrix -carboxyglutamic acid (MGLA) protein is a vitamin K dependent peptide which contributes to the immunomodulatory activity of mesenchymal stromal cells. There is a possible association between MGLA protein and inflammatory bowel disease (IBD) which is divided into Crohn’s disease (CD) and ulcerative colitis (UC). However, little is known about the clinical utility of MGLA protein in IBD patients. This study aimed to assess the impact of achieving remission on the serum MGLA protein levels in IBD patients. This prospective observational study included 60 newly diagnosed IBD patients. All patients were subjected to full clinical, laboratory, radiological, and histopathological assessment of IBD at baseline and six months after initiating treatment. Serum MGLA protein level was assessed using an enzyme-linked immunosorbent assay. There were 29 (48.3%) UC cases and 31 (51.67%) CD cases. We observed a significant decrease in serum MGLA protein levels after 6 months of treatment compared to pretreatment values in UC patients (120.490 ± 26.273 vs. 26.320 ± 17.378 nmol/L, p<0.001) and CD patients (125.576 ± 28.208 vs. 28.520 ± 18.443 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent UC patients before treatment (142.556 ± 17.096 vs. 110.560 ± 23.659 nmol/L, p<0.001) and after six months of treatment (51.222 ± 4.410 vs. 15.114 ± 3.302 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent CD patients before treatment (150.727 ± 7.198 vs. 111.743 ± 25.718 nmol/L, p<0.001) and after six months of treatment (52.182 ± 5.269 vs. 15.506 ± 4.475 nmol/L, p<0.001). This response was irrespective of the therapeutic modality. In conclusion, achievement of remission in IBD patients resulted in a significant decrease in serum MGLA protein levels.]]></description><issn>1110-4902</issn><issn>2090-2506</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqVj11qwzAQhEVpIabNUy6w78Xpyo5j_FxaeoC8i42zThSkyGjVNH7saXq8XqHqzwUKAwMzw8Cn1ELjsml0XT_w0S5rjSvsrlRRYYdl1eD6WhVaayxXHVYzNRc5IqKumnbdtoVKmwOD9SP1CcIA1B8sn-1pD5G9FbHhBPZbgyPvKYU4wTa8sYOdFSZhyIPRkXiCXEd7gc_3j7KnuA2Xae9eE-WYYYwhcT5yfGYnd-pmICc8__Nbdf_8tHl8KfsYRCIPZozWU5yMRvPDZjKb-WWr_7f-AtGRWV4</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Mohamed, Ghada</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241001</creationdate><title>The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels</title><author>Mohamed, Ghada</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_55133_eji_3104093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Mohamed, Ghada</creatorcontrib><creatorcontrib>Department of Internal Medicine, Gastroenterology & Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt</creatorcontrib><collection>CrossRef</collection><jtitle>The Egyptian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohamed, Ghada</au><aucorp>Department of Internal Medicine, Gastroenterology & Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels</atitle><jtitle>The Egyptian journal of immunology</jtitle><date>2024-10-01</date><risdate>2024</risdate><volume>31</volume><issue>4</issue><spage>85</spage><epage>97</epage><pages>85-97</pages><issn>1110-4902</issn><eissn>2090-2506</eissn><abstract><![CDATA[Matrix -carboxyglutamic acid (MGLA) protein is a vitamin K dependent peptide which contributes to the immunomodulatory activity of mesenchymal stromal cells. There is a possible association between MGLA protein and inflammatory bowel disease (IBD) which is divided into Crohn’s disease (CD) and ulcerative colitis (UC). However, little is known about the clinical utility of MGLA protein in IBD patients. This study aimed to assess the impact of achieving remission on the serum MGLA protein levels in IBD patients. This prospective observational study included 60 newly diagnosed IBD patients. All patients were subjected to full clinical, laboratory, radiological, and histopathological assessment of IBD at baseline and six months after initiating treatment. Serum MGLA protein level was assessed using an enzyme-linked immunosorbent assay. There were 29 (48.3%) UC cases and 31 (51.67%) CD cases. We observed a significant decrease in serum MGLA protein levels after 6 months of treatment compared to pretreatment values in UC patients (120.490 ± 26.273 vs. 26.320 ± 17.378 nmol/L, p<0.001) and CD patients (125.576 ± 28.208 vs. 28.520 ± 18.443 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent UC patients before treatment (142.556 ± 17.096 vs. 110.560 ± 23.659 nmol/L, p<0.001) and after six months of treatment (51.222 ± 4.410 vs. 15.114 ± 3.302 nmol/L, p<0.001). Serum MGLA protein levels were significantly higher in non-remittent patients compared to remittent CD patients before treatment (150.727 ± 7.198 vs. 111.743 ± 25.718 nmol/L, p<0.001) and after six months of treatment (52.182 ± 5.269 vs. 15.506 ± 4.475 nmol/L, p<0.001). This response was irrespective of the therapeutic modality. In conclusion, achievement of remission in IBD patients resulted in a significant decrease in serum MGLA protein levels.]]></abstract><doi>10.55133/eji.310409</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1110-4902 |
| ispartof | The Egyptian journal of immunology, 2024-10, Vol.31 (4), p.85-97 |
| issn | 1110-4902 2090-2506 |
| language | eng |
| recordid | cdi_crossref_primary_10_55133_eji_310409 |
| source | Alma/SFX Local Collection |
| title | The impact of achieving remission in inflammatory bowel disease on plasma matrix -carboxyglutamate protein levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A56%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20achieving%20remission%20in%20inflammatory%20bowel%20disease%20on%20plasma%20matrix%20%EF%81%A7-carboxyglutamate%20protein%20levels&rft.jtitle=The%20Egyptian%20journal%20of%20immunology&rft.au=Mohamed,%20Ghada&rft.aucorp=Department%20of%20Internal%20Medicine,%20Gastroenterology%20&%20Hepatology%20Unit,%20Faculty%20of%20Medicine,%20Ain%20Shams%20University,%20Cairo%2011591,%20Egypt&rft.date=2024-10-01&rft.volume=31&rft.issue=4&rft.spage=85&rft.epage=97&rft.pages=85-97&rft.issn=1110-4902&rft.eissn=2090-2506&rft_id=info:doi/10.55133/eji.310409&rft_dat=%3Ccrossref%3E10_55133_eji_310409%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |